Neurocrine’s Crenessity Is The First New Drug For CAH In 70 Years

Next Competitor Likely Years Behind

 
• By Mandy Jackson
  
Neurocrine won FDA approval for Crenessity two weeks earlier than expected (Shutterstock)

More from Drug Pricing

More from Market Access